Corona Remedies Ltd Q1 FY27 Results Analysis: PAT Surges 30%, Margin Expands 191 bps

Corona Remedies Ltd reported Q1 FY27 numbers with revenue of Rs. 422.43 Cr (+21.90% YoY) and PAT growth of +30.10% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

CORONA delivered a strong Q1 with revenue growing 21.9% YoY, exceeding its 15% FY27 guidance. EBITDA margin expanded 191 bps to 22.05%, and PAT grew 30.1% YoY. The company gained market share, ranking 26th in IPM, and demonstrated operating leverage.

Key Investment Insights

Key Positives

• Revenue grew 21.9% YoY to Rs.422.43 Cr, above management's 15% FY27 revenue guidance.
• EBITDA grew 33.5% YoY to Rs.93.13 Cr, with margin expanding 191 bps YoY to 22.05%.
• PAT grew 30.1% YoY to Rs.60.11 Cr, above management's >20% PAT growth guidance.
• Market rank improved from 29th to 26th in IPM, fastest growing among top 30 companies.

Risk Factors

• Finance costs rose 35.2% YoY and 95% QoQ, though absolute level is low.
• Effective tax rate increased 140 bps YoY to 25.20%, reducing PAT.
• Depreciation grew 48.4% YoY due to capex cycle, pressuring net margins.